Providers utilize business intelligence to monitor referral patterns and collaborate with clinicians who order their services. Such analytics tools have also been deployed in the specialty to improve productivity, track patient satisfaction and bolster quality.
The insurance arm of UnitedHealth Group said the shift is part of its ongoing effort to eliminate the barriers between care delivery and medical coverage. The full list of services exempt from prior authorizations includes diagnostic tests and many outpatient surgeries.
WakeMed, a three-hospital system in the North Carolina capital region of Raleigh, would become part of Advocate Health, Atrium’s parent company, if the deal goes through. Advocate is one of the largest not-for-profit health systems in the U.S.
The New Jersey-based drug developer joins AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk and Pfizer in offering products directly to patients at a discounted rate. Johnson & Johnson is currently listing four medications on the platform.
The agency said it is seeking to exclude semaglutide, tirzepatide and liraglutide from the 503B program based on a lack of clinical evidence. Unless there’s a shortage, the pharmaceuticals would be barred from being compounded by third-parties for the purpose of treating diabetes or obesity. The FDA is seeking public comment on the proposal.
Healthcare research outfit KLAS is out with its 2023 Best in KLAS awards recognizing excellence in healthcare software and services, and the Sweden-based imaging IT and cybersecurity company Sectra tops the field of U.S. PACS vendors—again.
The American College of Radiology is cheering a Feb. 6 decision by a federal judge in Texas who ruled that parts of the independent dispute resolution (IDR) process in the Surprise Billing Final Rule violate the Administrative Procedure Act.
Radiology that facilitates the sharing of resources and touchpoints within an enterprise but across geographic locales is the future of the specialty, according to two Harvard radiology researchers.
A therapeutic oncology company has been cleared to market a cancer treatment that that turns a tumor’s own biology into a self-signaling target for radiation therapy.
Whatever specific shape work takes in the near and distant future, it’s likely the COVID-19 era will be looked back upon as a before-and-after dividing line.